SciSparc Ltd. (SPRC) stock
Close on Nov 11, 2026Market cap $145.52KP/E 0.0Yield –
SciSparc Ltd. saw revenue fall 34.5% to $856.00K over fiscal 2025. At the latest close the market valued the company at $145.52K, 0.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $145.52K
- P/E ratio
- 0.0
- Price to sales
- 0.17
- Price to book
- 0.04
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $856.00K
- Net income
- -$12.18M
- EPS, diluted
- $98.07
Trading
- Previous close
- $0.38
- Open
- $0.38
- Day's range
- $0.37 – $0.41
- Volume
- 138,557
- Average volume (20 days)
- 4,267,047
- Beta (5 years)
- 0.34
- 52-week range
- $0.37 – $29.88
- RSI (14 days)
- 15.9
- Volatility (1 year)
- 208.9%
- Relative volume
- 0.13×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SPRC | S&P 500 | Difference | SPRC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -91.1% | -2.4% | −88.7 pts | ||
| 3 months | -94.2% | -1.2% | −93.0 pts | ||
| Year to date | -96.7% | +12.3% | −109.0 pts | ||
| 1 year | -98.4% | +12.4% | −110.8 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -92.2% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.1 pts | -79.9% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases SciSparc filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About SciSparc
Pharmaceutical Preparations
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on creating and developing technologies and therapeutic assets based on cannabinoid treatments. Through its majority-owned subsidiary, NeuroThera Labs Inc., the company advances clinical programs utilizing Δ9-tetrahydrocannabinol and non-psychoactive cannabidiol to address central nervous system conditions. Its development pipeline includes SCI-110 for Tourette syndrome, Alzheimer’s disease, and agitation, as well as SCI-210 for autism spectrum disorder and status epilepticus. In addition, the company oversees early commercial initiatives for CannAmide, an oral palmitoylethanolamide tablet formulation intended for Canadian retail pharmacies, alongside an eCommerce subsidiary marketing hemp seed oil products on Amazon Marketplace.
Company profile, executives and historySciSparc stock: common questions
What is SciSparc's stock price?
SPRC closed at $0.40 on Nov 11, 2026, up 5.07% on the day. Over the past 52 weeks it traded between $0.37 and $29.88.
What is SciSparc's market cap?
SciSparc was worth $145.52K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SPRC's P/E ratio?
SPRC trades at 0.0 times earnings, based on diluted earnings per share of $98.07 over fiscal 2025.
How much revenue does SciSparc make?
SciSparc reported revenue of $856.00K for fiscal 2025, down 34.5% from a year earlier.
Does SciSparc pay a dividend?
No. SciSparc has not paid a cash dividend over the last twelve months.
How has SPRC stock performed over the past year?
Including dividends, SPRC returned -98.4% over the past year, against +12.4% for the S&P 500.
How many SPRC shares are sold short?
0M shares were sold short at the latest FINRA report, 22.49% of the float, or 1.0 days of average trading volume.
Who are SciSparc's competitors?
Companies most similar to SciSparc by business, industry and size include XTLB, RFL, SPRB, CANF, MNOV.
See a number that looks wrong?